Teva Highlights Long-Term Data From Chorea Associated-Huntington's Treatment

Teva Pharmaceutical Industries Ltd TEVA announced results from the ARC-HD trial, an approximately 3-year open-label study evaluating the safety and tolerability of long-term treatment with Austedo (deutetrabenazine) tablets for chorea associated with Huntington's Disease (HD).
ARC-HD results showed that treatment with Austedo had a safety and tolerability profile comparable with the First-HD 12-week study.
In ARC-HD, medication compliance rates were greater than 90% over the ~3 year open-label extension period.
Austedo improved and maintained chorea control in the Rollover and Switch cohorts.
In patients who rolled over from the pivotal study, from baseline to Week 8, there was a 4.5-point reduction in mean chorea scores. 7.1-point reduction in the mean total motor score (TMS).
In patients who switched overnight from tetrabenazine, from baseline to Week 8 there was a 2.1-point reduction in mean chorea scores and a 2.4-point reduction in mean TMS.
Price Action: TEVA shares are up 2.14% at $8.36 on the last check Tuesday.

Momentum49.53

Growth24.83

Quality28.96

Value18.92

Short

Medium

Long